Treatment of Glioblastoma Using Multicomponent Silica Nanoparticles

• DOI: 10.1002/adtp.201900118
• Publication Date: 2019-09-04T15:26:21Z
• Authors: Oguz Turan; Peter A. Bielecki; Vindya Perera; Morgan Lorkowski; Gil Covarrubias; Kathleen Tong; Aaron Yun; Georgia Loutrianakis; Shruti Raghunathan; Youngjun Park; Taylor Moon; Shane Cooley; Deobrat Dixit; Mark A. Griswold; Ketan B. Ghaghada; Pubudu M. Peiris; Jeremy N. Rich; Efstathios Karath...
• Keywords: Brain tumor

Abstract Glioblastoma multiforme (GBM) remains highly lethal. This partially stems from the presence of brain tumor initiating cells (BTICs), a plastic cellular subpopulation that is resistant to current therapies. In addition resistance, blood–brain barrier limits penetration most drugs into GBMs. To effectively deliver BTIC‐specific inhibitor tumors, multicomponent nanoparticle, termed Fe@MSN, which contains mesoporous silica shell and an iron oxide core, developed. Fibronectin‐targeting ligands direct nanoparticle near‐perivascular areas GBM. After Fe@MSN particles are deposited in tumor, external low‐power radiofrequency (RF) field triggers rapid drug release due mechanical tumbling particle resulting high amounts across interface widespread delivery The loaded with 1400W, potent inducible nitric synthase (iNOS). It shown iNOS preferentially expressed BTICs required for their maintenance. Using 1400W‐loaded RF‐triggered release, vivo studies indicate treatment disrupts BTIC population hypoxic niches, suppresses growth significantly increases survival BTIC‐derived GBM xenografts.